The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
about
The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
The use of 18F-Fluoro-deoxy-gl ...... 8835, a novel PI3Kα inhibitor.
@en
type
label
The use of 18F-Fluoro-deoxy-gl ...... 8835, a novel PI3Kα inhibitor.
@en
prefLabel
The use of 18F-Fluoro-deoxy-gl ...... 8835, a novel PI3Kα inhibitor.
@en
P2093
P2860
P1433
P1476
The use of 18F-Fluoro-deoxy-gl ...... 8835, a novel PI3Kα inhibitor.
@en
P2093
Alison Pritchard
Emily Lawrie
Francois-Xavier Ble
Herve Barjat
Juliana Maynard
Kevin Hudson
Sally-Ann Emmas
Urs Hancox
Urszula M Polanska
P2860
P304
P356
10.1371/JOURNAL.PONE.0183048
P407
P577
2017-08-14T00:00:00Z